Drug intelligence / Profile preview

ILB-2203

Development stage: Preclinical
Lead developer: Innolake Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ILB-2203 is a preclinical-stage bispecific antibody (BsAb) being developed by Innolake Biopharm for the treatment of autoimmune diseases. As a bispecific antibody, it is engineered to simultaneously bind to two different antigens or epitopes, a strategy intended to provide superior efficacy or more precise immune modulation compared to conventional monoclonal antibodies. The specific molecular targets of ILB-2203 have not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on ILB-2203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILB-2203.

Explore the full profile